Free Trial

Pekin Hardy Strauss Inc. Makes New Investment in The Chemours Company (NYSE:CC)

Chemours logo with Basic Materials background

Pekin Hardy Strauss Inc. acquired a new stake in The Chemours Company (NYSE:CC - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 300,607 shares of the specialty chemicals company's stock, valued at approximately $4,067,000. Pekin Hardy Strauss Inc. owned approximately 0.20% of Chemours at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new position in Chemours in the 1st quarter valued at approximately $27,000. UMB Bank n.a. lifted its position in Chemours by 73.9% in the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after acquiring an additional 948 shares in the last quarter. Quadrant Capital Group LLC lifted its position in Chemours by 100.4% in the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock valued at $38,000 after acquiring an additional 1,119 shares in the last quarter. Farther Finance Advisors LLC lifted its position in Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after acquiring an additional 1,444 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in Chemours in the 4th quarter valued at approximately $48,000. 76.26% of the stock is owned by institutional investors.

Insider Buying and Selling at Chemours

In other Chemours news, insider Damian Gumpel purchased 7,822 shares of the business's stock in a transaction on Tuesday, June 3rd. The stock was acquired at an average price of $9.95 per share, for a total transaction of $77,828.90. Following the purchase, the insider owned 131,701 shares of the company's stock, valued at approximately $1,310,424.95. This represents a 6.31% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Shane Hostetter purchased 4,450 shares of the business's stock in a transaction on Monday, May 19th. The stock was acquired at an average price of $11.28 per share, with a total value of $50,196.00. Following the purchase, the chief financial officer directly owned 59,694 shares in the company, valued at $673,348.32. This represents a 8.06% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 25,672 shares of company stock valued at $251,573 over the last 90 days. 0.47% of the stock is currently owned by company insiders.

Chemours Stock Performance

Shares of NYSE:CC traded up $0.28 during midday trading on Thursday, hitting $14.05. The company had a trading volume of 4,852,642 shares, compared to its average volume of 2,521,129. The company has a debt-to-equity ratio of 7.01, a current ratio of 1.75 and a quick ratio of 0.83. The company has a market cap of $2.10 billion, a price-to-earnings ratio of 70.23 and a beta of 1.65. The Chemours Company has a 12-month low of $9.13 and a 12-month high of $25.54. The company has a fifty day moving average of $11.32 and a two-hundred day moving average of $14.01.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.06). The company had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.36 billion. Chemours had a return on equity of 23.82% and a net margin of 0.54%. The company's revenue for the quarter was up .4% on a year-over-year basis. During the same quarter last year, the company earned $0.32 earnings per share. On average, equities research analysts expect that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Dividend Announcement

The business also recently disclosed a dividend, which was paid on Monday, June 16th. Stockholders of record on Monday, May 19th were paid a $0.0875 dividend. The ex-dividend date was Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's dividend payout ratio (DPR) is 175.00%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Truist Financial lowered their price target on Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Wall Street Zen cut Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Morgan Stanley lowered their price target on Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. UBS Group lowered their price target on Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Royal Bank Of Canada increased their price target on Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a report on Thursday, July 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $17.33.

View Our Latest Research Report on CC

Chemours Profile

(Free Report)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

See Also

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Should You Invest $1,000 in Chemours Right Now?

Before you consider Chemours, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.

While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

7 Nuclear Stocks One Announcement Away from Exploding

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines